Related Experiment Video
Updated: Jun 2, 2026
Teratoma Generation in the Testis Capsule
Published on: November 7, 2011
[Management of chorionic gonadotropin-producing seminoma]
N Boujelbene1, M Ozsahin, G Ugurluer
1Service de radio-oncologie, centre hospitalier universitaire Vaudois, rue du Bugnon 46, 1011 Lausanne, Suisse. abderrahim.zouhair@chuv.ch
Introduction:
The human chorionic gonadotropin (HCG)-producing seminoma is an uncommon entity and belongs to the overall category of pure seminoma.
Method:
The literature search was conducted on Medline(®) using the words: seminoma, human chorionic gonadotropin, HCG combined with radiotherapy, chemotherapy, surveillance, management and prognosis. We extended our search of similar references by related articles function, reading the bibliography of identified articles and publications available on Medline(®) from the same authors. This research was limited to English or French publications. Articles were eligible if they were randomized trials, prospective, retrospective or systematic reviews of the literature.
Results:
Few articles were found on this subject. We selected the most relevant series while summarizing various parameters (epidemiological, clinical, therapeutic and prognostic).
Conclusions:
Clinical presentation, behaviour and work-up for HCG-producing seminoma should be the same as for non-secreting seminoma. HCG-producing seminoma tumours are not more resistant to radiation therapy or chemotherapy than non-secreting seminoma tumours. Radiotherapy remains an excellent option in stage I and IIA disease with chemotherapy as an alternative; overall prognosis is excellent. Surveillance in early stage HCG-producing seminoma is followed by a higher relapse than in early stage non-secreting seminoma.
